Jinyun Chen
YOU?
Author Swipe
View article: Comparison of reproductive outcomes after ultrasound-guided high-intensity focused ultrasound and myomectomy for patients with uterine fibroids
Comparison of reproductive outcomes after ultrasound-guided high-intensity focused ultrasound and myomectomy for patients with uterine fibroids Open
Reproductive outcomes after USgHIFU were comparable to those after myomectomy. USgHIFU is a viable option for patients with fertility requirements and may also serve as a means to control the progression of UFs in patients without immediat…
View article: Efficacy of focused ultrasound ablation surgery in patients with adenomyosis and coexisting pelvic adhesions
Efficacy of focused ultrasound ablation surgery in patients with adenomyosis and coexisting pelvic adhesions Open
The preoperative assessment of pelvic adhesions plays a crucial role in predicting intraoperative adverse events of FUAS in patients with adenomyosis, as well as determining both short-term and long-term efficacy, thereby providing valuabl…
View article: Achieving NPVR ≥ 80% as technical success of high-intensity focused ultrasound ablation for uterine fibroids: a cohort study
Achieving NPVR ≥ 80% as technical success of high-intensity focused ultrasound ablation for uterine fibroids: a cohort study Open
View article: Causal Relationship Between Immune Cells and Endometrial Cancer: A Two- Sample Mendelian Randomization Study
Causal Relationship Between Immune Cells and Endometrial Cancer: A Two- Sample Mendelian Randomization Study Open
Background In the context of endometrial cancer (EC), immune cells are pivotal in influencing tumor progression and outcome, exerting effects predominantly via mechanisms of immune surveillance, evasion, and infiltration into the tumor mic…
View article: Long-term re-intervention after USgHIFU and prediction of NPVR in different ages of patients with uterine fibroids
Long-term re-intervention after USgHIFU and prediction of NPVR in different ages of patients with uterine fibroids Open
The long-term outcome of USgHIFU is promising. The re-intervention rate is related to NPVR in differently aged patients. Young patients need a high NPVR to reduce re-intervention risk.
View article: Achieving NPVR ≥ 80% as Technical Success of High-Intensity Focused Ultrasound Ablation for Uterine Fibroids: a cohort study
Achieving NPVR ≥ 80% as Technical Success of High-Intensity Focused Ultrasound Ablation for Uterine Fibroids: a cohort study Open
Objective: To report the long-term re-intervention of patients with uterine fibroids after ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation, and analyse the influencing factors of re-intervention in group of NPVR ≥80%…
View article: Prediction of non-perfusion volume ratio for uterine fibroids treated with ultrasound-guided high-intensity focused ultrasound based on MRI radiomics combined with clinical parameters
Prediction of non-perfusion volume ratio for uterine fibroids treated with ultrasound-guided high-intensity focused ultrasound based on MRI radiomics combined with clinical parameters Open
View article: The dose of focused ultrasound ablation surgery (FUAS) for unresectable pancreatic cancer is predictable: A multicenter retrospective study
The dose of focused ultrasound ablation surgery (FUAS) for unresectable pancreatic cancer is predictable: A multicenter retrospective study Open
To analyze the influencing factors of energy efficiency factors (EEF) in focused ultrasound ablation surgery (FUAS) for unresectable pancreatic cancer and build a dosimetry model. The patients with unresectable pancreatic cancer that under…
View article: Factors influencing USgHIFU ablation for adenomyosis with NPVR ≥ 50%
Factors influencing USgHIFU ablation for adenomyosis with NPVR ≥ 50% Open
To investigate the influencing factors of ultrasound-guided HIFU (USgHIFU) ablation for adenomyosis with a non-perfused volume ratio (NPVR)≥50%. A total of 299 patients with adenomyosis who underwent USgHIFU ablation were enrolled. Quantit…
View article: Long-term outcomes of ultrasound guided high intensity focused ultrasound ablation for patients with uterine fibroids classified by T2WI: a multicenter retrospective study
Long-term outcomes of ultrasound guided high intensity focused ultrasound ablation for patients with uterine fibroids classified by T2WI: a multicenter retrospective study Open
USgHIFU ablation is effective for hypointense, isointense, HHF and mHHF with acceptable long-term follow-up outcomes. However, sHHF is associated with a higher reintervention rate.
View article: Supplementary Table 2 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
Supplementary Table 2 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma Open
Supplementary Table 2 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
View article: Supplementary Figure 3 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
Supplementary Figure 3 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma Open
Supplementary Figure 3 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
View article: Supplementary Figure 4 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
Supplementary Figure 4 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma Open
Supplementary Figure 4 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
View article: Data from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
Data from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma Open
Pancreatic ductal adenocarcinoma is a disease of extremely poor prognosis for which there are no reliable markers of asymptomatic disease. To identify pancreatic cancer biomarkers, we focused on a genomic interval proximal to the most comm…
View article: Supplementary Figure 1 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
Supplementary Figure 1 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma Open
Supplementary Figure 1 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
View article: Supplementary Figure 1 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
Supplementary Figure 1 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma Open
Supplementary Figure 1 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
View article: Supplementary Table 3 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
Supplementary Table 3 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma Open
Supplementary Table 3 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
View article: Supplementary Table 4 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
Supplementary Table 4 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma Open
Supplementary Table 4 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
View article: Supplementary Table 2 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
Supplementary Table 2 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma Open
Supplementary Table 2 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
View article: Supplementary Table 3 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
Supplementary Table 3 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma Open
Supplementary Table 3 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
View article: Supplementary Figure Legends 1-4 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
Supplementary Figure Legends 1-4 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma Open
Supplementary Figure Legends 1-4 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
View article: Supplementary Table 1 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
Supplementary Table 1 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma Open
Supplementary Table 1 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
View article: Data from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
Data from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma Open
Pancreatic ductal adenocarcinoma is a disease of extremely poor prognosis for which there are no reliable markers of asymptomatic disease. To identify pancreatic cancer biomarkers, we focused on a genomic interval proximal to the most comm…
View article: Supplementary Figure 3 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
Supplementary Figure 3 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma Open
Supplementary Figure 3 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
View article: Supplementary Table 4 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
Supplementary Table 4 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma Open
Supplementary Table 4 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
View article: Supplementary Table 1 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
Supplementary Table 1 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma Open
Supplementary Table 1 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
View article: Supplementary Figure Legends 1-4 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
Supplementary Figure Legends 1-4 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma Open
Supplementary Figure Legends 1-4 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
View article: Supplementary Figure 2 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
Supplementary Figure 2 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma Open
Supplementary Figure 2 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
View article: Supplementary Figure 4 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
Supplementary Figure 4 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma Open
Supplementary Figure 4 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
View article: Supplementary Figure 2 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma
Supplementary Figure 2 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma Open
Supplementary Figure 2 from A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma